Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.84

+1.8%

Dec 19 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (1465)	8/25/2000 9:33:46 AM
From: Elmer	Read Replies (1) of 52153

Thank Richard, The following is a draft of your suggested e-mail to DNDN IR: "Thanks for your previous responses. Can you describe how the Mylovenge project differs from the vaccine work undertaken by IDEC Pharmaceuticals about 10 years ago? Also, I understand that Vical has a Phase I/II trial ongoing for a cancer vaccine for lymphoma. Did this trial influence the company's selection of multiple myeloma as an initial focus? If the Vical trials are successful, how will this effect Mylovenge's competitive picture?" Does this capture the questions you want answered? David

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next